Kazia Therapeutics expands Paxalisib trial into HR+/HER2- breast cancer
Kazia Therapeutics is expanding the Paxalisib clinical trial into HR+/HER2- breast cancer, citing preclinical data supporting strong clinical activity and safety. The three-arm expansion adds Paxalisib plus fulvestrant versus standard of care, with first patient expected soon.